Clinical report on treatment of 7 patients with refractory anemia by using cyclosporin A.
- Author:
Xiang-Rong KONG
1
;
Yi-Ming FENG
Author Information
1. Department of Cardiovascular Diseases, the Affiliated Hospital of Nanyang Medical Training School, Nanyang 473000, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Anemia, Refractory;
drug therapy;
Cyclosporine;
administration & dosage;
Drug Therapy, Combination;
Female;
Humans;
Male;
Middle Aged;
Stanozolol;
administration & dosage
- From:
Journal of Experimental Hematology
2004;12(5):697-698
- CountryChina
- Language:Chinese
-
Abstract:
To explore the treatment of refractory anemia (RA), 7 cases of myelodysplastic syndrome (subtype of refractory anemia) were treated in combination of cyclosporin A (CsA) with stanozolol. Duration of treatment with CsA was 5 months-3 years (mean 13 months). The results showed that among 7 cases 6 were effective, 1 case no responded to treatment. 3 cases out of 6 effective cases achieved complete remission without transfusion dependence, 1 cases achieved partial remission, 2 cases were improved. During the investigation signs of leukemia ot other malignant tumors not were found in all cases. In conclusion, CsA treatment is effective for part cases of RA, side effects of drugs are tolerable for patients.
